COPERNICUS: Ongoing phase 2 study of subcutaneous amivantamab plus lazertinib as first line treatment for EGFR mutated metastatic NSCLC

This opening section introduces the COPERNICUS study and frames it within the evolving treatment landscape for EGFR-mutated metastatic non–small cell lung cancer.

Explore the innovative Copernicus trial, evaluating subcutaneous Amivantamab plus Lazertinib for treating EGFR-mutated metastatic lung cancer.

Explore the benefits of subcutaneous Amivantamab, including reduced infusion reactions and improved patient experience in cancer treatment.

Discover how Copernicus enhances patient care with innovative treatments and supportive practices for advanced EGFR mutation cases.

This study explores the efficacy and safety of amivantamab plus lazertinib for patients with EGFR mutations and brain metastasis.